Deals

Unlike previous deals in this space which were mostly to do with discovering new compounds, the big pharma is paying $150m upfront to license a specific product.

During Q3, biopharmas brought in an aggregate $17bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.1m.

The new company, Rhine Pharma, hopes to avoid the isotope production issues that have dogged other radiopharmaceutical developers.

While big pharma has significantly higher R&D and acquisition expenditures, certain biotechs have outperformed in terms of ROI and have substantial potential for future growth with their strong pipeline assets.

Three $1bn+ alliances were penned in September.

Xbrane Biopharma is on the clock to bring in a licensing partner for one of its two biosimilar candidates in order to fulfil its short-term working capital requirements. The Swedish firm has revealed that a deal for one appears close, as it also reached an agreement for more time to put pen to paper.

With sales projected to peak at nearly $700m a year, Galafold – the first oral monotherapy for people living with the ultra-rare genetic disorder Fabry disease – is a lucrative target for ANDA sponsors. However, Teva, which has just put pen to paper on a patent-litigation settlement agreement, will have to wait more than a decade to roll out its generic product.

Kenvue may have to start sharing time with Bausch + Lomb in investors’ discussions about the outlook for success at US consumer health firms separated from former parent firms as they and their competitors begin reporting the results for their latest quarters.

Bodybuilding.com reintroduces itself as ‘BBCOM’ with new plans; Flashlight Capital bids to buy Korea tobacco giant’s ginseng business; Hello Cake acquires Trigg Laboratories to be vertically integrated; Actylis expands into supplements, OTCs with Pharm-Rx; Helaina adds $45M funding, launches ingredient sales; ophthalmic drug firm Scope adds Eyevitamins supplements; 5 Star Nutrition’s franchising to expand.

An interactive look at medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.